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ABSTRACT

POLYCHLORINATED BIPHENYL 153 EXACERBATES NONALCOHOLIC
FATTY LIVER DISEASE IN C57BU6 MICE

Banrida Wahlang
April 04,2012

Polychlorinated biphenyls (PCBs) are persistent environmental pollutants which
are detectable in the serum of all American adults. Amongst PCB congeners,
PCB 153 has the highest serum level. PCBs have been dose-dependently
associated with suspected nonalcoholic fatty liver disease (NAFLD), obesity and
metabolic syndrome in epidemiological studies. The purpose of this study is to
determine if PCB 153 induces NAFLD in mice fed a control diet (CD), and
exacerbates NAFLD in mice fed a high fat diet (HFD). C57BL6/J mice were fed
either control or 42% milk fat diet for 12 weeks with or without PCB 153 coexposure (50 mg/kg i.p. x 4). Glucose tolerance tests were performed, and
plasma/tissues were obtained at necropsy for measurements of adipocytokine
levels, histology, and gene expression microarrays. In mice fed CD, the addition
of PCB 153 had little to no effect on any of the measured parameters. In contrast,
PCB 153 co-exposure in high fat-fed mice was associated with dramatically
increased visceral adiposity, hepatic steatosis and increased plasma adipokines
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including adiponectin, leptin, resistin and plasminogen activator inhibitor-1 levels.
Likewise, co-exposure reduced expression of hepatic genes implicated in

~

oxidation while increasing the expression of genes associated with lipid
biosynthesis. Regardless of diet, PCB 153 had no effect on insulin resistance or
tumor necrosis factor alpha levels. However, HFD+PCB 153 appeared to induce
an endoplasmic reticulum (ER) stress response. Therefore, PCB 153 is an
obesogen which exacerbates hepatic steatosis; alters adipocytokines; and
disrupts normal hepatic lipid metabolism when administered with HFD. Because
all U.S. adults have been exposed to PCB 153, this particular nutrient-toxicant
interaction potentially impacts on the progression of human NAFLD.
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CHAPTER 1
INTRODUCTION
Polychlorinated biphenyls (PCBs)
Polychlorinated biphenyls (PCBs) are halogenated compounds consisting
of up to 10 chlorine atoms attached to a biphenyl group. They were
manufactured during 1930s-1970s and were used as dielectric and heat transfer
fluids in electric transformers, wax extenders, flame retardants and as a source
of chlorine content. A total of 1.3 million tons of PCBs containing about 130
congeners was manufactured worldwide prior to their banning in 1977 (1).
Monsanto, a well-known PCB manufacturer in North America, produced PCB
mixtures under the brand name Aroclor at several plants including Anniston,
Alabama. High-level environmental contamination during production resulted in
increased PCB body burden in Anniston residents (2). Although PCBs have been
banned for over 30 years, their high thermodynamic stability make them resistant
to chemical degradation in the environment and hence, PCBs, belong to the
category of 'persistent organic pollutants' (POPs). PCBs are still present in our
ecosystem, including the atmospheric air, lakes, rivers, fish, human adipose
tissue, serum and breast milk. Humans are exposed to PCBs through inhalation
of PCB-contaminated air or ingestion of PCB-contaminated food. In fact, PCBs
continue to be present in the food supply and daily intake in the American diet is

estimated to be approximately 30 ng/day based on a recent study from a Dallas
supermarket (3). PCBs are the 5th most hazardous substances on the CERCLA
priority list (2007). The National Health and Nutrition Examination Study
(NHANES) indicates that 100% of adult NHANES participants had detectable
circulating PCB levels and PCB 153 (2,2',4,4',5,5'-hexachlorobiphenyl) has the
highest median serum concentration in humans amongst all PCB congeners (5).

Non-alcoholic fatty liver disease (NAFLO)
A previous study from our laboratory group identified suspected nonalcoholic fatty liver disease (NAFLD) and toxicant associated steatohepatitis
(TASH) in the NHANES participants with chronic low-level environmental
exposures to POPs including PCBs (4). NAFLD represents a pathological
spectrum of diseases ranging from lipid accumulation in the hepatocytes
(steatosis) to the development of superimposed inflammation (steatohepatitis)
and ultimately fibrosis and cirrhosis. NAFLD is the most prevalent liver disease in
North America. It resembles alcoholic fatty liver disease although it occurs in
non-alcoholic subjects. The pathogenesis of NAFLD has been reviewed (5), and
key mechanisms include altered adipo-cytokines with low adiponectin and high
leptin levels (5, 6) and production of pro-inflammatory cytokines such as TNFa
and IL-6 (7). NAFLD gives rise to hepatic insulin resistance and systemic
inflammation, which in turn, induces obesity, diabetes and the metabolic
syndrome (8, 9). Moreover, NAFLD is also exacerbated by diabetes (10) and is
associated with obesity (5). Because it is often seen in association with insulin
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resistance and dyslipidemia, NAFLD is generally regarded to be the hepatic
manifestation of obesity and the metabolic syndrome. Interestingly, inflamed and
fatty liver conditions are not confined to obese individuals only, but other factors
can predispose a person to steatohepatitis. Therefore, it is possible that primary
factors such as consumption of hyper-caloric foods can lead to steatosis in
normal individuals but secondary factors such as POPs can act as a second hit
and worsen this effect, leading to a diseased state.
Effects of PCB exposure in humans
Our laboratory group recently identified advanced steatohepatitis
associated with insulin resistance and increased pro-inflammatory cytokines in
non-obese chemical workers who were subjected to high-level industrial
chemical exposures. The term TASH was then coined to describe this condition
(11). Our initial work was focused on TASH in non-obese vinyl chloride workers;
in our recent work however, our laboratory group identified suspected
NAFLDITASH in NHANES participants with low-level environmental exposures to
POPs including PCBs (4, 11). Other epidemiologic studies have found
associations between PCBs and metabolic disorders associated with NAFLD
including obesity (12, 13), insulin resistance/diabetes (14-16), and the metabolic
syndrome (13,17). Furthermore, follow-up of subjects involved in the "Yu-cheng"
incident in Taiwan, one of the two known major human PCB intoxication
episodes, where cooking oil had been highly contaminated by PCBs, the
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mortality rate due to cirrhosis was 2.7 -fold higher than expected (18), although
pathologic confirmation was not provided.
Structure-activity and toxicity relationship
The PCB's structure determines the compound's activity and toxicity.
Based on the chlorine substitution in the two phenyl rings, PCBs can be
classified as either planar or non co-planar (Figure 1). Planar PCBs have chlorine
substitutions in either the meta- or para- positions but not in the ortho- positions.
Non co-planar PCBs have ortho- substituted chlorine atoms, apart from metaand/or para- substitutions. PCB studies focused on hepatocarcinogenesis and
receptor-based mechanisms including the aryl hydrocarbon receptor (AhR)
(coplanar or dioxin-like PCBs), the constitutive androstane receptor (CAR) (noncoplanar or non-dioxin-like PCBs), and more recently, the estrogen receptor (1921). The AhR is a member of the PAS domain protein family of transcription
factors and regulates a battery of genes involved with xenobiotic detoxification
including CYP1 A and CYP1 B which can, in turn, bio-transform or activate procarcinogens to their carcinogenic forms. Depending on the type of PCB-receptor
interaction, PCBs have a tendency to induce pro-carcinogens leading to
carcinogenicity or they can cause hepatomegaly and fatty liver. Coplanar PCBs
such as PCB 126 are AhR agonists similar to dioxin (22). Previous work has
implicated dioxins and dioxin-like PCBs in animal models of steatohepatitis (23,
24). However, by mass, dioxin-like PCBs are a relatively minor component of the
total PCB burden in human serum (4). Moreover, PCBs do not appear to be as
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carcinogenic in man as they are in rodents (eg: PCB 126), and this may be due
to differences in the AhR structure and in the battery of target genes between
species (25). From a mechanistic standpoint, a PCB's structure determines its
ability to interact with nuclear receptors as well. A theoretical structure-activity
relationship study predicted that ortho-substituted PCBs can interact with the
pregnane-X-receptor (PXR), estrogen receptor(ER), androgen receptor (AR) and
thyroid receptor (TR) (26). PCB 153, an ortha-substituted, non co-planar PCB
(Figure 1) has been studied extensively by the National Toxicology Program
(NTP) in female Harlan Sprague-Dawley (SO) rats and the mode of action has
been attributed to the compound's interaction with CAR (27-29). The studies also
demonstrated PCB-induced hepatotoxicity (20, 27). Furthermore, nutrienttoxicant interactions appear to be important in diet-induced obesity/metabolic
syndrome (30) and NAFLD (5). However, the effect of PCB 153, a lipid soluble,
non-dioxin like PCB which concentrates in adipose tissue has not been
adequately studied in animal models of NAFLD.
PCB's metabolism is defined by the number of chlorine atoms present.
Low molecular weight PCBs (mono-, di-, tri- or tetra-chlorinated) are hydroxylated
by cytochrome P450 enzymes (31). The metabolized PCBs, also known as
biotransformed congeners, can form DNA adducts or bind to proteins to exert
their toxic effects. High molecular weight PCBs, on the other hand, do not
metabolize, hence they are known as persistent congeners. These PCBs such as
the hexa-chlorinated PCB 153, bioaccumulate in the adipose tissue (32).

5

Planar

o

Non co-planar

0, "

"GI

GI

~-==.,

o
CI
PCB 153
CI

CI

CI

CI

CI

CI

Figure 1. Chemical structure of PCBs.
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Significance of the study
Obesity has been identified as a leading "preventable cause of death" by
the World Health Organization (WHO), and many health authorities view it as one
of the most serious health problems of the 21 st century (25). The annual cost of
obesity treatment in the US alone was recently estimated at $147 billion (1).
According to the data from NHANES 2007-2008,33.8% of US adults are obese
(defined by body mass index, BMI
(defined by BMI

~

~

30) with another 34.2% being overweight

25) (26). Alarmingly, obesity is not restricted to the adult

population; 15% of children and adolescents in the US are obese (27).
Overweight/obesity is one of the defining features of metabolic syndrome,
a metabolic disorder which is also characterized by insulin resistance,
hypertension, and dyslipidemia (28). The prevalence of metabolic syndrome in
US adults was recently estimated at 34.3% (29). The obesity epidemic is strongly
associated with increased type 2 diabetes which is the late stage of insulin
resistance. The National Diabetes Fact Sheet obtained from the Center for
Disease Control and Prevention (CDC, 2011) reports that 25.8 million Americans
have diabetes with another 79 million being insulin resistant. Obesity, insulin
resistance, and metabolic syndrome eventually lead to target organ damage
including fatty liver disease, cardiovascular disease, chronic kidney disease, and
cancer.
The pathogenesis of obesity, insulin resistance, and the metabolic
syndrome is complex. Historically, obesity was blamed on over-nutrition and
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genetic background. However, recent literature reports implicated NAFLD (2,

30,31) and persistent organic pollutants such as PCBs (3-10,12-15,32) as
key players in the development of obesity and the metabolic syndrome.
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CHAPTER 2

PCB 153 WORSENS DIET INDUCED OBESITY IN C57BU6 MICE
INTRODUCTION
Epidemiologic studies have implicated PCBs in metabolic disorders
associated with NAFLD including obesity (12, 13), insulin resistance/diabetes
(14-16), and the metabolic syndrome (13,17). Moreover, PCB 153 had the
highest median serum levels in NHANES participants, than any single PCB
congener. It therefore becomes crucial to evaluate the role of PCB 153 in
induction of obesity or worsening diet-induced obesity.
In this study, PCB 153 is hypothesized to act as a relevant "second hit"
mechanism in the genesis and progression of NAFLD occurring in the context of
a high fat diet. The first purpose of this study is to determine, if PCB 153 alone is
capable of inducing NAFLD in mice fed a control diet (normal chow diet). The
second purpose of the study is to determine if PCB exposures increase NAFLD
occurring on a background of diet-induced obesity by worsening previously
implicated mechanisms such as insulin resistance.
C57BL6/J mice were used in our 12 week study. The mice were fed either
control diet or 42% milk fat diet with or without PCB 153 co-exposure (50 mg/kg
i.p. x 4). NAFLD is characterized by hepatic steatosis, inflammation and
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dysregulation in adipokine levels. The objective of our study is to validate if the
PCB 153-exposed animals gain weight, showed steatosis, insulin resistance or
any other form of metabolic disorder.
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MATERIALS AND METHODS
Animals and diets. The animal protocol was approved by the University of

Louisville Institutional Animal Care and Use Committee. Male C57BU6J mice (8
weeks old, n=40; The Jackson Laboratory, Bar Harbor, Maine) were divided into
4 study groups (n=10) based on diet and PCB 153 exposure in this 12 week
study utilizing a 2x2 design. Mice were fed either a high fat diet (HFD, 42% kCal
from fat; TD.88137 Harlan Teklad) or a control diet (CD, 13.5% kCal from fat;
5010 LabDiet). Diet composition is shown in Table 1. PCB 153 (Ultra Scientific,
North Kingstown, RI), was administered in corn oil (vehicle) by IP injection (vs.
corn oil alone) at a dose of 50 mg/kg on weeks 4, 6, 8, and 10 (200mg/kg of PCB
153 cumulative). This dose was chosen based on previous NTP TR 530 study
(3000 Ilg/kg by gavage, 5 days per week for 14 weeks:::: 210 mg/kg of PCB 153
cumulative) (28). Mice were housed in a temperature-and light-controlled room
(12h light; 12h dark) with food and water ad libitum. Glucose tolerance tests were
performed at week 11, and the animals were euthanized (sodium pentobarbital,
40 mg/kg body weight, i.p.) at the end of week 12. Thus four different treatment
groups were evaluated in this fashion: CD, CD+PCB 153, HFD, HFD+PCB.
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High Fat Diet

Control Diet
%kCal

Source

%kCal

Source
Casein

Protein

28.5

Soybean Meal

15.2

Carbohydrate

58.0

Starch/Sucrose

42.7

Fat

13.5

Ether extract

42

Table 1. Diet composition.
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Sucrose/Corn
starch
Milk Fat

Glucose tolerance test. The glucose tolerance test (GTT) was performed 2
weeks prior to the end of study. On the day of test, mice were fasted for 6 h (9
A.M.-3 P.M.) and fasting blood glucose level was measured with a hand-held
glucometer (ACCU-CHEK Aviva, Roche, Basel, Switzerland) using 1 III blood via
tail snip. Glucose was then administered (1 mg glucose/g body weight, sterile
saline, i.p.), and blood glucose was measured at 5, 15,30,60,90 and 120 min
post-injection. Insulin resistance was calculated by homeostasis model
assessment (HOMA) using the formula HOMA-IR = Fasting glucose (mg/dL) x
Fasting insulin

(~U/mL)

/405 (20).

Liver histological studies. Liver sections were frozen using optimal cutting
temperature (OCT), a liquid embedding medium, or fixed in 10% buffered
formalin for 24 h and embedded in paraffin for histological examinations. Tissue
sections were stained with either Oil Red

a (frozen OCT), hematoxylin-eosin

(H&E; formalin-fixed) or Sirius red stain (formalin-fixed) and examined under light
microscopy at 200X magnification. Photomicrographs were captured using a
Nikon Eclipse E600 Microscope.

Liver enzymes, lipids and TNFa mRNA measurements. Plasma aspartate
transaminase (AST), alanine transaminase (ALT), cholesterol, triglyceride, high
density lipoprotein (HDL) and low density lipoprotein (LDL) levels were measured
using Cobas Mira Plus automated chemical analyzer (Roche, Basel,
Switzerland). Real-time polymerase chain reaction (RT -PCR) experiments were
used to measure hepatic tumor necrosis factor alpha (TN Fa) mRNA. Animal liver
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was homogenized and total RNA was extracted using the RNA-STAT 60 protocol
(Tel-Test, Austin, TX). cDNA was synthesized from total RNA using the
QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA). PCR was
performed on the Applied Biosystems StepOnePlus Real-Time PCR Systems
using the Taqman Universal PCR Master Mix (Life Technologies, Carlsbad, CA).
Primer sequence for TNFa (Mm00443258-m1) was obtained from Taqman Gene
Expression Assays (Applied Biosystems, Foster City, CA). The levels of mRNA
were normalized relative to the amount of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (4352932E). Expression levels in mice fed CD and
administered vehicle were set at 100%. Gene expression levels were calculated
according to the 2-MCt method (33).
Measurement of hepatic triglyceride and cholesterol content. Frozen mouse
livers were washed in neutral 1X phosphate buffered saline and pulverized.
Hepatic lipids were extracted by an aqueous solution of chloroform and
methanol, according to the Bligh and Dyer method (21), dried using nitrogen and
re-suspended in 5% lipid free bovine serum albumin. Triglycerides and
cholesterol were quantified using the Cobas Mira Plus automated chemical
analyzer. The reagents employed for the assay were L-Type Triglyceride M
(Wako Diagnostics, Richmond, VA) and Infinity Cholesterol Liquid Stable
Reagent (Fisher Diagnostics, Middletown, VA) for triglycerides and cholesterol
respectively.
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Statistical Analysis. Statistical analyses were performed using GraphPad Prism
version 5.01 for Windows and SigmaPlot 11.01. Data are expressed as mean ±
SEM. For 2 group comparison, an unpaired t-test was used, and multiple group
data were compared using Two Way ANOVA followed by Tukey Test for posthoc all pairwise comparisons. P <0.05 was considered statistically significant.
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RESULTS

PCB 153 treatment increased body weight and visceral adiposity in mice
fed high fat diet, but had no effect in mice fed control diet.
During the 12 week experiment, all groups experienced weight gain
(Figure 2). PCB 153 administration had no significant effect on mean percent
body weight gain in mice fed CD (111.10 ± 0.75% for CD

VS.

107.50 ± 1.73% for

CD+PCB 153). In contrast, PCB 153 significantly increased body weight gain in
mice fed with HFD (122.80 ± 1.98%)

VS.

HFD+vehicle (114.40 ± 2.56%, P <0.05).

There was a significant interaction between HFD and PCB 153 using Two Way
ANOVA (p =0.002).
On H&E stain, epididymal adipocyte size was increased by HFD, but PCB
153 had no additive effect (Figure 3). In mice fed with CD, the mean epididymal
adipocyte area (~m2) was 1357.95 ± 70.73 ~m2 with vehicle control and this was
significantly increased with PCB 153 (1806.46 ± 169.46 ~m2, p=0.02) (Figure 4).
In mice fed HFD, adipocyte size was not significantly different for vehicle
(5643.82 ± 632.49 ~m2)

VS.

PCB 153 (5371.29 ± 484.91 ~m2). However,

adipocyte size was significantly larger with HFD+vehicle

VS.

both CD+vehicle and

CD+PCB 153 (p <0.05). Likewise, mean adipocyte size was larger with
HFD+PCB 153

VS.

both CD+vehicie and CD+PCB 153 (p <0.05). Therefore, PCB

153 increased diet-induced obesity, independent of effects on adipocyte size.
PCB 153 slightly increased adipocyte size only in mice fed CD.

16

*
130

..,

*

120

.J:.

0')

.~

110

~

"OJo

~

100~--~~~--r-~-

Figure 2. PCB 153 increased body weight and visceral adiposity in mice fed
HFD.
The % increase in body weight for C57BU6J mice (n=10) treated with a 42% milk
fat diet (vs. CD) ± PCB 153 (200 mg/kg cumulative) . Body weight measurements
were taken from week 1 to week 12 (12 weeks) and the body weight at week 1
was taken as 100%. Data are expressed as mean ± SEM. * P <0.05. CD-control
diet, HFD-high fat diet, PCB-polychlorinated biphenyl.

17

CD

CD+PCB 153

HFD

HFD+PCB 153

Figure 3. H&E staining showed HFD increased adipocyte cell size and this
was unaffected by PCB 153.
Epipdidymal adipose tissue was stained with H&E and images were captured
using a Nikon Eclipse E600 Microscope. The adipocyte cell size was increased in
mice fed with HFD and th is effect was not changed with PCB 153 coadministration. CD-control diet, HFD-high fat diet, PCB-polychlorinated biphenyl.
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Figure 4. HFD increased adipocyte cell size <.,..m 2 ) and this was unaffected

by PCB 153.
Adipocyte area was measured and the average cell size of > 100 cells for each of
the groups (n=1 0) was calculated. The adipocyte cell size (11m2) was increased in
mice fed with HFD and th is effect was not changed with PCB 153 coadministration. Data are expressed as mean ± SEM. * P <0.05. CD-control diet,
HFD-high fat diet, PCB-polychlorinated biphenyl.
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PCB 153 worsened NAFLD in mice fed high fat diet, but had no hepatic
effects in mice fed control diet.
CD-fed mice did not develop significant steatosis by histology (Oil Red 0
and H&E stains-Figure 5 & 6) with either vehicle control or PCB 153. In contrast,
HFD increased steatosis which appeared to be even greater with PCB 153 coexposure (vs. vehicle).
Hepatic necro-inflammation was evaluated by histology (H&E), plasma
aminotransferase activity, and hepatic TNFa message (RT-PCR). Qualitatively,
significant necro-inflammation was not observed histologically in either group
(Figure 6). Mean plasma AST activity levels were slightly, but significantly higher
with HFD+PCB 153 (54.13 ± 4.65 U/L) vs. either CD+vehicie (37.09 ± 1.99 U/L, P
<0.05) or CD+PCB 153 (37.68 ± 1.17 U/L, P <0.05) (Figure 7). The mean AST
level in the HFD+vehicle group (49.85±4.52 U/L) was significantly different vs.
CD+vehicie group (p <0.05) but not vs. CD+PCB 153. Mean plasma ALT activity
levels were not significantly different between groups (Figure 8). Hepatic TNFa
message was measured by RT PCR and normalized to GAPDH. Mean TNFa
message levels were not significantly different between groups: CD+vehicle (100
± 24.03); CD+PCB 153 (106.90 ± 40.06); HFD+vehicie (285.57 ± 109.73);
HFD+PCB 153 (60.47 ± 16.81). Hepatic fibrosis was evaluated by Sirius red
stain. As no qualitative differences were observed between treatment groups
(data not shown), quantitative studies were not performed.
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Hepatic triglycerides and cholesterol were quantitated biochemically. In
CD-fed mice, mean hepatic triglycerides were not significantly different between
vehicle (7.29 ± 1.20 Ilg/mg tissue) and PCB 153 treatment (4.63 ± 1.85 Ilg/mg
tissue) (Figure 9). Likewise, hepatic cholesterol levels were not significantly
different between vehicle (2.75 ± 0.39 Ilg/mg tissue) and PCB 153 (3.15 ± 0.93
Ilg/mg tissue) treated mice fed with CD (Figure 10). In contrast, HFD-fed mice
had significantly higher mean hepatic triglyceride levels with PCB 153 (56.37 ±
14.36 Ilg/mg tissue)

VS.

vehicle control (17 ± 6.35 Ilg/mg tissue, p <0.05). Indeed,

HFD+PCB 153 co-exposure resulting in significantly higher hepatic triglycerides
than all other treatments. Hepatic cholesterol levels were not significantly
different between HFD+vehicie (5.08 ± 1.49 Ilg/mg tissue)

VS.

HFD+PCB 153

(9.26 ± 2.21 Ilg/mg tissue). However, mean hepatic cholesterol levels were
significantly higher with HFD+PCB 153

VS.

both CD+vehicle or CD+PCB 153

(Figure 10).
In summary, the combination of PCB 153 and HFD dramatically increased
steatosis, marginally worsened necro-inflammation, but had no effect on fibrosis.
PCB 153 had no effect on these parameters in mice fed CD.
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CD

CD+PCB 153

HFD

HFD+PCB153

Figure 5. Oil Red 0 staining of liver tissue.
Oil Red 0 staining of hepatic sections established the occurrence of microvesicular steatosis in the HFO+PCB 153 mice. There was no evidence of microvesicular steatosis in mice fed CO without or with PCB 153 co-administration.
CD-control diet, HFO-high fat diet, PCB-polychlorinated biphenyl.
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CD+PCB153

CD

HFD

HFD+ PCB 153

Figure 6. H&E staining of liver tissue.
H&E staining of hepatic sections established the occurrence of macro-vesicular
steatosis in the HFD+PCB 153 mice. Macro-vesicular steatosis was not observed
in mice fed CD without or with PCB 153 co-administration . CD-control diet, HFDhigh fat diet, PCB-polychlorinated biphenyl.
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Figure 7. Effects of HFD and PCB 153 on plasma AST levels.
Plasma AST levels (U/L) were measured (n=10) using Cobas Mira Plus
automated chemical analyzer. The AST levels were significantly higher for the
HFD+PCB 153 group as compared to CD or CD+PCB 153. Data are expressed
as mean ± SEM . * P <0.05 . CD-control diet, HFD-high fat diet, PCBpolychlorinated biphenyl , AST-aspartate transaminase .
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Figure 8. Effects of HFD and PCB 153 on plasma ALT levels.
Plasma ALT levels (U/L) were measured (n=10) using Cobas Mira Plus
automated chemical analyzer. No significant change was observed in any group.
Data are expressed as mean ± SEM. * P <0.05. CD-control diet, HFD-high fat
diet, PCB-polychlorinated biphenyl, AL T-alanine transaminase.
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Figure 9. Effects of HFD and PCB 153 on hepatic triglyceride levels.
Hepatic levels of triglyce rides were quantified (Ilg/mg tissue) in mice (n=5) fed
with control or high fat diet with or without PCB 153. PCB 153 increased hepatic
triglyceride levels in mice fed a HFD. Data are expressed as mean ± SEM. * P
<0.05. CD-control diet, HFD-high fat diet, PCB-polychlorinated biphenyl.
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Figure 10. Effects of HFD and PCB 153 on hepatic cholesterol levels.
Hepatic levels of cholesterol were quantified

( ~g/mg

tissue) in mice (n=5) fed with

control or high fat diet with or without PCB 153. PCB 153 increased hepatic
cholesterol levels in mice fed a HFD. Data are expressed as mean ± SEM. * P
<0.05. CD-control diet, HFD-high fat diet, PCB-polychlorinated biphenyl.
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Insulin resistance, glucose regulation and serum lipoproteins: Effects of
HFD and PCB 153.
In order to evaluate insulin resistance which may complicate obesity,
HOMA-IR was determined and GTT was performed. As observed by HOMA-IR
(Figure 11) HFD+vehicie (3.80 ± 0.48) was associated with insulin resistance but
this effect was not augmented by HFD+PCB 153 (3.83 ± 0.62). However, HOMAIR levels were significantly higher in HFD+vehicle vs. CD+vehicie (1.26 ± 0.17)
and CD+PCB 153 (1.30 ± 0.35, P <0.05). Likewise, HOMA-IR levels were
significantly higher in HFD+PCB 153 vs. CD+vehicie and CD+PCB 153 (p
<0.05). GTT was performed and compared to CD; PCB 153 had no additive
effect to dietary manipulation alone (Figure 13). However, in CD-fed mice, PCB
153 administration was associated with lower fasting blood glucose levels
(170.40 ± 4.57 mg/dL for CD+vehicie vs. 147.10 ± 5.92 mg/dL CD+PCB 153,
p=0.006) (Figure 12). Furthermore, HFD+vehicie and HFD+PCB 153 significantly
increased the glucose area under the curve (AUC) (Figure 13 & 14) (p <0.05)
which was obtained from GTT.
The plasma levels of total cholesterol, triglycerides, high density
lipoproteins (HDL) and low density lipoproteins (LDL) were measured in all
animal groups (Table 2). No significant differences in total cholesterol,
triglycerides, LDL and HDL were observed in mice administered CD+vehicle vs.
CD+PCB 153. Likewise mean lipid levels were unchanged in HFD+vehicle vs.
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HFO+PCB 153. However, total cholesterol, LOL, and HOL were significantly
higher for HFO+PCB 153 vs. CO+PCB 153 (p <0.05 - Table 2).
In summary, HFO was associated with insulin resistance and serum
hypercholesterolemia, but PCB 153 had no additional effect on these
parameters.
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Figure 11. HFD increased insulin resistance and this was unaffected by
PCB 153 co-exposure.
HOMA-IR was caluclated from fasting blood glucose and insulin levels for all four
groups of animals (n=10). HFD and HFD+PCB 153 groups showed higher levels
of HOMA-IR, indicative of insulin resistance , as compared to CD and CD+PCB
153 groups. Data are expressed as mean ± SEM. * P <0.05. CD-control diet,
HFD-high fat diet, PCB-polychlorinated biphenyl.
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Figure 12. Fasting blood glucose levels.
Fasting blood glucose levels (mg/dL) were measured for all animals. HFD and
HFD+PCB 153 showed higher fasting blood glucose levels when compared to
CD group. CD+PCB 153 showed significantly lower fasting blood glucose levels
when compared to CD alone . Data are expressed as mean ± SEM. * P <0.05.
CD-control diet, HFD-high fat diet, PCB-polychlorinated biphenyl.
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Figure 13. Glucose tolerance test (GTT).
Glucose tolerance test was performed and blood glucose levels were measured
for mice (n=10) fed with a control or high fat diet, with or without PCB 153. High
fat diet increased glucose tolerance and this was unaffected by PCB 153. CDcontrol diet, HFD-high fat diet, PCB-polychlorinated biphenyl.
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Figure 14. Area under the curve calculated from GTT.
Area under the curve was calculated from the glucose tolerance test readings.
HFD and HFD+PCB 153 groups showed higher AUC levels than CD or CD+PCB
153 groups. Data are expressed as mean ± SEM. * P <0.05. CD-control diet,
HFD-high fat diet, PCB-polychlorinated biphenyl.
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CD

CD+PCB 153

Cholesterol

70.01 ± 10.29

69.88 ± 16.50

Triglycerides

33.85 ± 12.95

38.63 ± 19.86

HDL

54.73 ± 5.07

58.85 ± 10.92

HFD

HFD+PCB 153

136.78 ±

141.52 ±

37.65 a

27.49a

23.39 ± 4.17

34.17 ± 27.11

111.01 ±

113.80 ±

31.02
LDL

14.03 ± 2.39

14.29 ± 4.07

a

33.74 ± 9.67a

17.69a
31.25 ± 8.79

a

Table 2. Plasma levels of total cholesterol, triglycerides, high density and
low density lipoproteins
ap

<0.05 compared with mice fed CD alone or co-administered with PCB 153.

Values are mean ± SEM (mg/dL). CD-control diet, HFD-high fat diet, PCBpolychlorinated biphenyl, HDL-high density liporoteins, LDL-Iow density
lipoproteins.
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DISCUSSION
The most striking result of this study was the synergistic interaction
between PCB 153 and HFD resulting in dramatically increased obesity.
Historically, exposures to PCBs, and the related molecule TCDD, have been
associated with wasting syndrome, although hypercaloric diets were not utilized
(34,35). Consistent with these historical observations, a decrease in % body
weight gain was observed in the CD-fed mice administered with PCB 153

VS.

vehicle control. However, recent epidemiological studies, which did not control for
diet, revealed an association between serum levels of specific PCB congeners
and human obesity (12, 13). Likewise, an increase in % body weight gain
corresponding with qualitatively increased visceral fat was observed in mice with
PCB 153+HFD co-exposure

VS.

HFD alone. These seemingly paradoxical

findings could potentially be explained by (i) the fact that PCB 153 is not an AhR
agonist as are the PCBs used in most prior rodent studies, (ii) AhR has
dramatically different activities in rodents and humans (36), and (iii) unlike the
rodent studies, in the epidemiologic studies, humans are simultaneously being
exposed to hypercaloric diets. Although we can retrospectively rationalize our
findings, they were nonetheless unexpected. Therefore, metabolic cages were
not used and adiposity was not precisely quantitated. We were, however, able to
quantitate adipocyte size which showed that PCB 153 had no effect on adipocyte
size over HFD alone.

35

Despite changes in obesity, PCB 153 was not associated with increased
insulin resistance (HOMA-IR). However some alterations were observed in
glucose metabolism. There was a non-significant trend towards higher AUC
levels (glucose tolerance test) with significantly lower fasting blood glucose levels
in CD-fed mice co-administered with PCB 153 which theoretically could be
explained by CAR activation (37). Notably, PCB 153 was associated with human
diabetes in adult NHANES (15), indicating that other factors may have driven
insulin resistance. A more recent prospective human study determined that
higher baseline levels of PCBs with greater than 7 chlorine atoms (and not PCB
153 that has six chlorines) were associated with the subsequent development of
greater BMI, insulin resistance, and triglycerides (38). Therefore, it appears that
the effects of PCBs on obesity/metabolic syndrome may be congener-dependent
and depend on affinity for the AhR and degree of chlorination.

Concordant with the increase in obesity, PCB 153 worsened NAFLD in
HFD mice. Steatosis was dramatically increased by the combination of PCB
153+HFD. In contrast to steatosis, which increased considerably, hepatic necroinflammation was only minimally increased by HFD+PCB 153. While mean
plasma AST activity was significantly increased in this group, no significant
changes were observed in ALT, necro-inflammation by histology, hepatic TNFa
message levels, or plasma levels of TNFa, IL-6, or IL-10. Previous
epidemiological study from our laboratory found a dose-dependent association
between plasma PCB levels and elevated ALT in adult NHANES subjects (4).
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However, weaker associations were also noted between PCBs and elevated AST
levels. PCB 153 was not associated with hepatic inflammation, although
preliminary in vitro studies from our laboratory showed that PCB exposures
increased TNFa production from Raw 264.7 cells, a murine macrophage cell line
(39). However, these differences could be PCB congener/dose specific or related
to differences between in vitro vs. in vivo systems.
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CHAPTER 3
MECHANISMS BY WHICH PCB 153 PROMOTE OBESITY
INTRODUCTION
The characteristics of NAFLD/obesity include but are not limited to hepatic
steatosis, insulin resistance and increased serum cholesterol. Adipokine
dysregulation is another probable factor that drives NAFLD towards metabolic
syndrome. Furthermore, in our studies, there was marked evidence for the
occurrence of hepatic steatosis in mice fed a HFD and co-exposed to PCB 153.
Deposition of fat in the liver can occur through different mechanisms such as
increased synthesis and decreased catabolism of fat in liver (40) or increased
import of fat to liver and decreased export to other tissues (24). We therefore
measured the serum levels of adipokines such as adiponectin, leptin, resistin and
tissue plasminogen activator inhibitor (t-PAI 1) as well as cytokines.
To further understand the mechanism that led to steatosis, mRNA
expression of enzymes involved in fatty acid metabolism was examined. These
enzymes included fatty acid synthase (FAS) for fatty acid synthesis, PPARa and
carnitine palmitoyl transferase 1A and 2 (CPT1A and 2) for fatty acid oxidation.
The mRNA expression of fatty acid binding protein 1 (FABP1), utilized for fatty
acid transport, was also examined.
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Another aspect that we studied is related to the slight increase in
adiponectin levels in the plasma as compared to the high fold-change observed
with leptin in the HFD+PCS 153 group. We hypothesize that the decreased
adiponectin:leptin ratio seen in this group may be due to endoplasmic reticulum
(ER) stress brought upon by PCS exposure in high fat-fed mice.
ER stress refers to the phenomenon when the protein load in the ER
exceeds the ER folding capacity; hence, also known as unfolded protein
response (UPR) (41). Synthesis, folding and maturation of secreted and
transmembrane proteins occur in the endoplasmic reticulum (ER). ER is also the
site of lipid biosynthesis and calcium (Ca 2+) storage. Causes of ER stress are
diverse and range from Ca 2 + to cholesterol accumulation and phospholipid
depletion (42).
One of the defining features in ER stress is the upregulation of the CAATenhancer binding protein (C/ESP) homologous protein 10 (CHOP 10), also
known as DNA damage-inducible transcript 3 (DOlT 3) (43). CHOP-10 belongs to
the family of bliP C/ESP like transcription factors and has been implicated in ER
stress, oxidative stress and nutrient deprivation (44, 45). UPR is an adaptive
mechanism initiated by the cell in response to demand for protein folding. The
presence of misfolded proteins in ER attracts immunoglobulin heavy chain
binding protein (SiP); SiP's principal role is to bind to ER stress transducers in
their inactive form towards it (41). Dissociation of the chaperone protein SiP from
the ER stress transducer protein kinase RNA-activated (PKR)-like ER kinase
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(PERK) leads to phosphorylation of the translation initiation factor 2 (eIF2a)
(Figure 15). Phosphorylation of elF2a leads to nuclear translocation of activating
nuclear transcription 4 (ATF4) which induces CHOP 10 (46, 47). CHOP 10 plays
a functional role in apoptosis, diabetes mellitus and adipocyte differentiation (45,
48,49).
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Figure 15. Upregulation of CHOP 10 in endoplasmic reticulum (ER) stress.
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Growth and differentiation of preadipocytes involve a complex sequence
of transcription factors that are interdependent and can either stimulate or inhibit
adipocyte differentiation, eventually affecting adipocyte genes and adipocyte
secretory hormone levels.
Adipocytes or fat cells arise from fibroblasts that require growth arrest and
terminal differentiation to become functional and matured adipocytes. Growth
arrest is controlled by CAAT -enhancer binding protein alpha (C/EBPa) and
peroxisome proliferator-activated receptor gamma (PPARy), transcription factors
that transactivate adipocyte-specific genes (48). C/EBPa increases p21 (cyclindependent kinase inhibitor) levels and has anti-mitotic activity (50) while PPARy
decreases the transcriptional activity of E2F/DP-1 complex which controls DNA
synthesis (51). PPARy attains maximal level of expression in matured
adipocytes. C/EBPI3, a transcriptional activator of C/EBPa and C/EBPo,
precedes C/EBPa expression. CHOP 10 is expressed in growth arrested
preadipocytes and it transiently sequesters C/EBPI3 by heterodimerization (52).
C/EBPI3 and C/EBPo co-expression is essential for PPARy expression (53), thus
these transcription factors have temporal and spatial expressions that influence
each other. Therefore, CHOP 10 is a negative modulator of the C/EBP
transcriptional activity and its upregulation leads to decreased C/EBPI3 and
C/EBPo levels, which subsequently repress C/EBPa and PPARy expression.
Suggested PPARy target genes include adiponectin, lipoprotein lipase (LPL) and
adipocyte protein 2 (aP2) or fatty acid binding protein 4 (FABP4) (54, 55).
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MATERIALS AND METHODS
Cytokines and adipokines measurement. Plasma cytokine and adipokine

levels were measured using Milliplex Mouse Serum Cytokine and Adipokine Kits
(Millipore Corp, Billerica, MA) on the Luminex IS 100 system (Luminex Corp,
Austin, TX), as per the manufacturer's instructions.
Real time-PCR. Mouse liver and adipose tissue samples were homogenized and

total RNA was extracted using the RNA-STAT 60 protocol (Tel-Test, Austin, TX).
cDNA was synthesized from total RNA using the QuantiTect Reverse
Transcription Kit (Qiagen, Valencia, CA). PCR was performed on the Applied
Biosystems StepOnePlus Real-Time PCR Systems using the Taqman Universal
PCR Master Mix (Life Technologies, Carlsbad, CA). Primer sequences (Taqman
Gene Expression Assays) were obtained from Applied Biosystems (Foster City,
CA) and included the following (with the catalogue number): fatty acid synthase
(FAS) (Mm00662319-m 1), peroxisome proliferator-activated receptor alpha
(PPARa) (Mm00440939-m1), carnitine palmitoyltransferase 1A (CPT1A)
(Mm01231183-m1), carnitine palmitoyltransferase 2 (CPT2) (Mm00487205-m1),
fatty acid binding protein 1 in liver (FABP1) (Mm00444340-m1), peroxisome
proliferator-activated receptor gamma (PPARy) (Mm01184322-m1), CCAATenhancer-binding protein alpha (C/EBPa) (Mm00514283-s1), C/EBP
homologous protein (CHOP 10) (Mm00492097 -m 1) and glyceraldehyde-3phosphate dehydrogenase (GAPDH) (4352932E). The levels of mRNA were
normalized relative to the amount of GAPDH mRNA, and expression levels in
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mice fed CD and administered vehicle were set at 100%. Gene expression levels
were calculated according to the 2-MCt method (33).
Statistical Analysis. Statistical analyses were performed using GraphPad Prism
version 5.01 for Windows and SigmaPlot 11.01. Data are expressed as mean ±
SEM. For 2 group comparison, an unpaired t-test was used, and multiple group
data were compared using Two Way ANOVA followed by Tukey Test for posthoc all pairwise comparisons. P <0.05 was considered statistically significant.
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RESULTS
PCB 153 altered plasma adipokine levels and expression although cytokine
levels were unchanged.

HFD+PCB 153 increased leptin levels 56-fold
and 25-fold

VS.

VS.

CD+vehcile (p <0.05);

CD+PCB 153 (p <0.05) (Table 3). Three additional adipokines,

adiponectin, resistin and tPAI-1, were also determined (Table 3). Compared to
the large magnitude changes observed in plasma leptin levels, adiponectin levels
were changed by a smaller amount. Adiponectin levels were higher in
HFD+vehicie

VS.

CD+vehicie and CD+PCB 153. Likewise, adiponectin levels

were higher in HFD+PCB 153

VS.

both CD and CD+PCB 153. Resistin levels

were significantly increased in HFD+PCB 153

VS.

both HFD+vehicle and

CD+vehicie (p <0.05). Resistin levels were also significantly higher in
HFD+vehicie
CD+PCB 153

VS.
VS.

CD+vehicie (p <0.05). No differences were noted between
any other group. Similarly, mean plasma tPAI-1was

significantly increased in HFD+PCB 153

VS.

HFD+vehicie and

VS.

CD+vehicie (p

<0.05). tPAI-1 levels were also significantly higher in HFD+vehicle

VS.

CD+vehicle (p <0.05). Plasma cytokines were measured and no change was
observed in any of the animal groups for the pro-inflammatory cytokines, TNFa
and IL-6, and the anti-inflammatory cytokine IL-10 (Table 3). Therefore,
HFD+PCB 153 co-exposures led to significant changes in adipokines including
the adiponectin, leptin, resistin, and tPAI-1; but did not affect cytokines including
TNFa, IL-6, or IL-10.

45

Adipocytokines

CD

CD+PCB 153

HFD

HFD+PCB 153

6.57 ± 0.38

9.01 ± 0.87

Adiponectin

6.39 ± 0.30

a

11.33 ± 1.11 a

(J.lg/mL)

1279.28 ±

116.67±
254.87 ± 55.46

Leptin (pg/mL)

360.11

39.93

941.09 ±

742.02 ±
Resistin (ngl mL)

a

838.02 ± 246.11
310.87

134.44
152.47±

a

71.32

3550.89

a

1359.99 ±
325.47a,b

363.80 ±

533.39 ±

142.82a

207.82 a,b

218.05 ± 91.06

tPAI-1 (ng/mL)

6543.00 ±

TNFa (pg/mL)

0.52 ± 0.49

0.65 ± 0.70

0.99 ± 1.44

0.58 ± 0.88

IL-6 (pg/mL)

3.80 ± 2.62

5.31 ± 5.79

12.69 ± 13.07

6.65 ± 8.12

IL-10 (pg/mL)

1.54 ± 0.33

1.42 ± 0.27

3.55 ± 3.03

2.68 ± 2.90

Table 3. Plasma cytokines' and adipokines' levels
ap

<0.05 compared with mice fed CD alone or co-administered with PCB 153.

b

p<0.05 compared with mice fed HFD alone. Values are mean ± SEM. CD-control
diet, HFD-high fat diet, PCB-polychlorinated biphenyl, tPAI-1-tissue plasminogen
activator inhibitor 1, TNFa-tumor necrosis factor alpha, IL-interleukin.
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PCB 153 exposure altered gene expression of enzymes involved in hepatic
lipid metabolism.
Real-time PCR was performed with total liver mRNA to analyze potential
changes in expression of selected genes involved in fatty acid metabolism: FAS,
PPARa, and CPT1A12.
FAS expression was significantly increased in HFD+PCB 153 (2530.53 ±
1436.48)

VS.

CD+vehicie (100 ± 39.30, P <0.05) and

VS.

CD+PCB 153 (422.05 ±

169.58, p <0.05) (Figure 16). Lower FAS expression was observed in
HFD+vehicie (472.78 ± 382.25)

VS.

HFD+PCB 153, and this was statistically

significant (p <0.05). Interestingly, HFD+vehicie showed significantly higher FAS
expression when compared to CD+vehicie group.
PPARa expression was significantly decreased in HFD+PCB 153 (19.09 ±
7.89)

VS.

CD+PCB 153 (112.64 ± 35.08, P <0.05) and

VS.

CD+vehicie (100 ±

19.51, P <0.05) (Figure 17). No significant differences were seen in PPARa
expression in HFD+vehicie (40.98 ± 13.17)

VS.

any other group; although there

was a non-significant trend towards higher PPARa

VS.

HFD+PCB 153. CPT1A, a

PPARa target gene and the rate limiting step in hepatic
decreased in HFD+PCB 153 (13.83 ± 6.85)

VS.

~

oxidation, was

CD+vehicle (100 ± 22.63, P

<0.05) (Figure 18). Mean CPT2 expression was significantly decreased in
HFD+PCB 153 (14.58 ± 5.53)
HFD+vehicie (49.72 ± 29.45)

VS.
VS.

CD+vehicle (100 ± 15.15, P <0.05); and also in
CD+vehicle (p <0.05) (Figure 19). CPT2

expression was numerically lower in HFD+PCB 153 than HFD+vehicle, but this
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observed trend was not statistically significant. FABP1 gene expression did not
differ significantly between PCB-exposed and unexposed groups fed either a
control or HFD.
Therefore, with HFD+PCB 153 co-exposure, the overall picture favored
increased expression of genes implicated in fatty acid synthesis and decreased
expression of genes involved in mitochondrial fatty acid
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Figure 16. HFD and PCB exposure altered expression of FAS in liver.
Real-time PCR experiments showed the changes in hepatic mRNA expressions
for fatty acid synthase (FAS) in mice liver caused by either PCB 153 exposure or
HFD consumption or both as compared to gene expression in mice fed CD
without or with PCB 153 exposure. All values were normalized to CD group ,
(n=10). Data are expressed as mean ± SEM . * P <0.05. CD-control diet, HFDhigh fat diet, PCB-polychlorinated biphenyl.
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Figure 17. HFD and PCB exposure altered expression of PPARa in liver.
Real-time PCR experiments showed the changes in hepatic mRNA expressions
for peroxisome proliferation activator alpha (PPARa) in mice liver caused by
either PCB 153 exposure or HFD consumption or both as compared to gene
expression in mice fed CD without or with PCB 153 exposure. All values were
normalized to CD group, (n=10) . Data are expressed as mean ± SEM . * P <0.05.
CD-control diet, HFD-high fat diet, PCB-polychlorinated biphenyl.
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Figure 18. HFD and PCB exposure altered expression of CPT1 A in liver.
Real-time PCR experiments showed the changes in hepatic mRNA expressions
for carnitine palmitoyl transferase 1A (CPT1 A) in mice liver caused by either PCB
153 exposure or HFD consumption or both as compared to gene expression in
mice fed CD without or with PCB 153 exposure. All values were normalized to
CD group, (n=10). Data are expressed as mean ± SEM. * P <0.05. CD-control
diet, HFD-high fat diet, PCB-polychlorinated biphenyl.
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Figure 19. HFD and PCB exposure altered expression of CPT2 in liver.
Real-time PCR experiments showed the changes in hepatic mRNA expressions
for carn itine palmitoyl transferase 2 (CPT2) in mice liver caused by either PCB
153 exposure or HFD consumption or both as compared to gene expression in
mice fed CD without or with PCB 153 exposure . All values were normalized to
CD group, (n=10). Data are expressed as mean ± SEM . * P <0.05. CD-control
diet, HFD-high fat diet, PCB-polychlorinated biphenyl.
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The role of PCB 153 in endoplasmic reticulum stress.
Our RT -PCR studies on the adipose tissue of C57BI/6 mice fed either CD
or HFD with or without PCB 153 co-administration showed interesting results that
suggested the role of PCBs as ER stress inducers in the presence of HFD. RTPCR was performed on mRNA extracted from the mouse adipose tissue for
adiponectin, CHOP 10, C/EBPa and PPARy.
Adiponectin mRNA levels decreased significantly in the HFD+PCB 153
group (2.77 ± 1.06) and HFD+vehicie group (24.90 ± 16.92) when compared to
CD+vehicle (100 ± 23.66, P <0.05) (Figure 20). CHOP 10 mRNA expression
increased significantly in the HFD+vehicie (610.89 ± 194.73) and HFD+PCB 153
group (325.66 ± 139.06) vs. CD+vehicie (100 ± 37.30, P <0.05) (Figure 21).
C/EBPa showed a trend towards lower mRNA expression in HFD+vehicie and
HFD+PCB 153 groups when compared to CD+vehicle or CD+PCB 153 groups
(Figure 22) . PPARy mRNA expression (Figure 23) decreased significantly for the
HFD+PCB 153 group (11.42 ± 2.43) as compared to CD+vehicie group (100 ±
39.40, p <0.05), suggesting a probable ER-stress response in these animals.
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Figure 20. HFD and PCB exposure altered expression of adiponectin in
adipose tissue.
Real-time PCR experiments showed the changes in adiponectin mRNA
expression in the adipose tissue caused by either PCB 153 exposure or HFD
consumption or both as compared to gene expression in mice fed CD without or
with PCB 153 exposure. All values were normalized to CD group, (n=5). Data are
expressed as mean ± SEM. * P <0.05. CD-control diet, HFD-high fat diet, PCBpolychlorinated biphenyl.
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Figure 21. HFD and PCB exposure altered expression of CHOP 10 in
adipose tissue.
Real-time PCR experiments showed the changes in CHOP 10 mRNA expression
in the adipose tissue caused by either PCB 153 exposure or HFD consumption
or both as compared to gene expression in mice fed CD without or with PCB 153
exposure. All values were normalized to CD group, (n=6). Data are expressed as
mean ± SEM. * P <0.05. CD-control diet, HFD-high fat diet, PCB-polychlorinated
biphenyl.
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Figure 22. HFD and PCB exposure altered expression of C/EBPa in adipose
tissue.
Real-time PCR experiments showed the changes in C/EBPa mRNA expression
in the adipose tissue caused by either PCB 153 exposure or HFD consumption
or both as compared to gene expression in mice fed CD without or with PCB 153
exposure. All values were normalized to CD group, (n=4). Data are expressed as
mean ± SEM .. CD-control diet, HFD-high fat diet, PCB-polychlorinated biphenyl.
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Figure 23. HFD and PCB exposure altered expression of PPARy in adipose
tissue.
Real-time PCR experiments showed the changes in PPARy mRNA expression in
the adipose tissue caused by either PCB 153 exposure or HFD consumption or
both as compared to gene expression in mice fed CD without or with PCB 153
exposure. All values were normalized to CD group, (n=7). Data are expressed as
mean ± SEM. * P <0.05. CD-control diet, HFD-high fat diet, PCB-polychlorinated
biphenyl.
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DISCUSSION
PCBs are known to concentrate within adipose tissue and liver, so it is not
surprising that these were the principal target sites for PCB 153 toxicity in this
study. Although PCB 153 levels were not measured, we expect them to be
similar to those in the NTP TR 530 14-week study (16). The NTP protocol
resulted in the following PCB 153 levels: lipid adjusted serum-1788 ng/g; liver34,010 ng/g; and adipose-1 ,118,300 ng/g. Thus, PCB 153 accumulates in the
adipose tissue and is likely to exert its effects at this site.

In our results, PCB 153 exposure to the HFD group altered multiple
adipokines including leptin, tPAI-1, resistin and adiponectin. Adiponectin, also
referred to as GBP-28, apM1, AdipoQ or Acrp30, is an adipocyte-derived
protein hormone which is encoded by the AD/POQ gene in humans (56).
Adiponectin regulates glucose and fatty acid catabolism (57) and its plasma
levels in adults are inversely proportional to body fat percentage (58). Literature
reports have demonstrated adiponectin's role in suppressing metabolic
derangements that can occur due to obesity (55), type 2 diabetes mellitus (58),
atherosclerosis (57) and metabolic syndrome (59). Interestingly, the plasma
levels of leptin were increased to a greater extent in the HFD+PCB 153 group as
compared to adiponectin. Leptin, a 30 kDa protein hormone encoded by the
Ob(Lep) gene, is also secreted by the adipocytes and plays a crucial role in
modulating energy intake and expenditure as well as appetite suppression (60,
61). Circulating levels of leptin are directly correlated with body fat mass and
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adipocyte size, with increasingly high levels seen in obesity (62). The overall
increase in adiposity in the HFO+PCB 153 animals may be responsible for the
increased circulating levels of leptin. Our results indicated that the observed
disproportion of adiponectin to leptin increment in the plasma of animals treated
with HFO+PCB 153 was due to increased adiposity and probably increased leptin
/decreased adiponectin production in the adipose tissue.

Steatosis was dramatically increased by the combination of PCB
153+HFO, whereas PCB 153 had no effect in mice fed CD. Steatosis is
determined by the rates of lipid synthesis, oxidation, uptake, and export. The RTPCR results suggest that PCB 153+HFO co-exposures increased hepatic lipid
synthesis (up-regulated FAS) while decreasing

~-oxidation

(down-regulated

CPT1A and CPT2 and its transcription factor, PPARa). Therefore, PCB 153
seemed likely to increase hepatic steatosis in mice fed HFO by altering
adipokines, increasing hepatic lipid synthesis, and decreasing hepatic

~

oxidation. This hypothesis will be investigated further in future studies.

RT-PCR results showed a marked decrease in adiponectin expression
levels in the adipose tissue. Interestingly, adiponectin plasma levels were
increased in this group. This can be explained by increased fat mass in these
animals that led to overall higher adiponectin secretion while the adiponectin
synthesis per fat cell was decreased. The resulting adiponectin mRNA
expression observed in the adipose tissue led us to hypothesize that PCB 153
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may act as an ER stress inducer in the adipose tissue in the presence of HFD.
We therefore looked at the mRNA expression of proteins that playa major role in
ER stress response, namely, CHOP 10 which is upregulated in ER stress,
C/EBPa, required for adipocyte differentiation and negatively regulated by CHOP
10, and PPARy, a positive transcription factor for adiponectin. Indeed, mRNA
expression was increased for CHOP 10 and repressed for CEBPa. PPARy
mRNA expression was also reduced in PCB 153-exposed mice fed with HFD.

In general, HFD consumption and PCB 153 co-exposure led to increased
lipogenesis in the liver by upregulation of FAS, and a decrease in PPARa
mediated fatty

acid-~-oxidation.

Furthermore, there is evidence of adipokine

dysregulation in the HFD+PCB 153 group. These finding s are important because
they implicate PCB 153 exposure in hepatic steatosis and adipokine
dysregulation, hallmarks of the metabolic syndrome. The presence of an ER
stress response is also speculated in the adipose tissue due to low adiponectin
secretion. However, this study requires further investigation.
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SUMMARY

PCBs are poly-halogenated hydrocarbons which are persistent
contaminants in our environment. Exposure to PCBs including the ubiquitous
PCB 153 has been dose dependently linked to increased odds ratio for serum
alanine aminotransferase elevation, indicative of NAFLD. To determine if
PCB153 plays a casual role in the development of NAFLD, a study was
undertaken to determine if PCB 153 either caused NALFD by itself or worsened
NAFLD induced by HFD consumption.
It was observed that PCB153 exposure caused an increase in % body
weight for animals fed a HFD. PCB 153 exposure also caused micro-vesicular
steatosis in animals fed a HFD and worsened HFD-induced macro-vesicular
steatosis. Serum adipokines were increased with HFD and this effect was
augmented by PCB 153 co-administration. PCB 153 treatment increased liver
triglycerides and cholesterol levels in the HFD group of animals. FAS expression
was upregulated and PPARa expression downregulated in the liver of animals
fed a HFD and co-exposed to PCB 153. The adiponectin mRNA level decreased
in the HFD+PCB153 group.
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In conclusion, PCB 153 is a diet-dependent obesogen, which also
worsens NAFLD via adipokine dysregulation and altered lipid metabolism. These
experimental results suggest that the previously observed associations between
PCB levels and human obesity/NAFLD may be causal. Nutrient-toxicant
interactions in obesity, metabolic syndrome, and NAFLDITASH warrant further
study.
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